Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Palisade Bio (NASDAQ:PALI) from a hold rating to a sell rating in a report released on Saturday morning.

Other analysts have also issued research reports about the stock. B. Riley Financial initiated coverage on shares of Palisade Bio in a research note on Friday, January 9th. They set a “buy” rating and a $7.00 price target for the company. Citigroup reissued a “buy” rating on shares of Palisade Bio in a research report on Tuesday, November 11th. Piper Sandler initiated coverage on shares of Palisade Bio in a report on Monday, December 29th. They issued an “overweight” rating and a $25.00 target price on the stock. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research note on Monday, December 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Palisade Bio presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Palisade Bio Stock Performance

PALI stock opened at $1.64 on Friday. The stock’s 50 day simple moving average is $1.90 and its 200 day simple moving average is $1.51. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.64. The company has a market cap of $244.36 million, a P/E ratio of -0.77 and a beta of 1.58.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.06). Equities analysts predict that Palisade Bio will post -12.43 earnings per share for the current year.

Hedge Funds Weigh In On Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. Total Clarity Wealth Management Inc. purchased a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 29,935 shares of the company’s stock, valued at approximately $70,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.